Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and PD-1 therapy for relapsed/refractory Hodgkin lymphoma
NCT06190067Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in Classical Hodgkin Lymphoma (cHL). Primary endpoint: Overall Response Rate at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
azacitidine
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT06190067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190067.